PTC Therapeutics, Inc. (PTCT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
PTCT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PTCT Revenue Analysis (2014–2025)
As of March 2, 2026, PTC Therapeutics, Inc. (PTCT) generated trailing twelve-month (TTM) revenue of $1.78 billion, reflecting solid growth of +7.2% year-over-year. The most recent quarter (Q3 2025) recorded $211.0 million in revenue, up 18.0% sequentially.
Looking at the longer-term picture, PTCT's 5-year compound annual growth rate (CAGR) stands at +35.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.73 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PTCT's business is primarily driven by Collaboration and License Revenue (55%), Product (32%), and Royalty (13%). With over half of revenue concentrated in Collaboration and License Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), PTCT has underperformed the peer group in terms of revenue growth. Compare PTCT vs AGIO →
Peer Comparison
Compare PTCT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PTCTCurrent | $1.8B | +7.2% | +35.4% | 50.1% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.73B | +114.5% | $0 | - | $866.9M | 50.1% |
| 2024 | $806.8M | -14.0% | $749.4M | 92.9% | $-302,570,000 | -37.5% |
| 2023 | $937.8M | +34.2% | $872.3M | 93.0% | $-439,502,000 | -46.9% |
| 2022 | $698.8M | +29.7% | $654.1M | 93.6% | $-447,409,000 | -64.0% |
| 2021 | $538.6M | +41.4% | $506.3M | 94.0% | $-374,443,000 | -69.5% |
| 2020 | $380.8M | +24.0% | $361.8M | 95.0% | $-431,768,000 | -113.4% |
| 2019 | $307.0M | +16.0% | $294.8M | 96.0% | $-241,158,000 | -78.6% |
| 2018 | $264.7M | +36.2% | $252.1M | 95.2% | $-115,685,000 | -43.7% |
| 2017 | $194.4M | +135.0% | $189.8M | 97.6% | $-64,292,000 | -33.1% |
| 2016 | $82.7M | +124.9% | $-34,928,000 | -42.2% | $-132,058,000 | -159.7% |
See PTCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTCT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PTCT vs AGIO
See how PTCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PTCT's revenue growth accelerating or slowing?
PTCT maintains +7.2% revenue growth, in line with its 5-year CAGR of +35.4%. TTM revenue stands at $1.8B. Growth rate remains consistent with historical average.
What is PTCT's long-term revenue growth rate?
PTC Therapeutics, Inc.'s 5-year revenue CAGR of +35.4% reflects the sustained expansion pattern. Current YoY growth of +7.2% is near this long-term average.
How is PTCT's revenue distributed by segment?
PTCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.